Which option correctly matches the ECHO and TRIANGLE trials with their key findings in frontline mantle cell lymphoma?
ECHO showed that acalabrutinib plus BR was superior to BR alone; TRIANGLE showed that adding ibrutinib may allow autologous transplant to be safely omitted.
ECHO showed that adding ibrutinib may allow autologous transplant to be safely omitted; TRIANGLE showed that acalabrutinib plus BR was superior to BR alone.
ECHO showed compelling efficacy with a chemotherapy-free BTK inhibitor combination in TP53-mutated patients; TRIANGLE established acalabrutinib-rituximab for older, frail patients.